Annual EBITDA
-$189.27 M
-$14.06 M-8.03%
December 31, 2023
Summary
- As of February 7, 2025, ADPT annual EBITDA is -$189.27 million, with the most recent change of -$14.06 million (-8.03%) on December 31, 2023.
- During the last 3 years, ADPT annual EBITDA has fallen by -$44.93 million (-31.13%).
- ADPT annual EBITDA is now -400.21% below its all-time high of -$37.84 million, reached on December 31, 2017.
Performance
ADPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$24.57 M
+$13.98 M+36.27%
September 30, 2024
Summary
- As of February 7, 2025, ADPT quarterly EBITDA is -$24.57 million, with the most recent change of +$13.98 million (+36.27%) on September 30, 2024.
- Over the past year, ADPT quarterly EBITDA has increased by +$36.50 million (+59.77%).
- ADPT quarterly EBITDA is now -219.22% below its all-time high of -$7.70 million, reached on September 30, 2018.
Performance
ADPT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$163.50 M
+$16.34 M+9.09%
September 30, 2024
Summary
- As of February 7, 2025, ADPT TTM EBITDA is -$163.50 million, with the most recent change of +$16.34 million (+9.09%) on September 30, 2024.
- Over the past year, ADPT TTM EBITDA has increased by +$25.77 million (+13.61%).
- ADPT TTM EBITDA is now -1299.03% below its all-time high of -$11.69 million, reached on March 31, 2018.
Performance
ADPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ADPT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.0% | +59.8% | +13.6% |
| 3 y3 years | -31.1% | +47.6% | +23.5% |
| 5 y5 years | -332.6% | +47.6% | +23.5% |
ADPT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -8.0% | +2.1% | at high | +59.8% | -3.6% | +23.5% |
| 5 y | 5-year | -168.1% | +2.1% | -11.1% | +59.8% | -131.6% | +23.5% |
| alltime | all time | -400.2% | +2.1% | -219.2% | +59.8% | -1299.0% | +23.5% |
Adaptive Biotechnologies EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$24.57 M(-36.3%) | -$163.50 M(-9.1%) |
| Jun 2024 | - | -$38.55 M(-2.0%) | -$179.85 M(-0.0%) |
| Mar 2024 | - | -$39.33 M(-35.6%) | -$179.85 M(-5.0%) |
| Dec 2023 | -$189.27 M(+8.0%) | -$61.06 M(+49.3%) | -$189.27 M(+18.7%) |
| Sep 2023 | - | -$40.91 M(+6.1%) | -$159.51 M(+1.0%) |
| Jun 2023 | - | -$38.55 M(-20.9%) | -$157.88 M(-5.0%) |
| Mar 2023 | - | -$48.75 M(+55.7%) | -$166.22 M(-5.1%) |
| Dec 2022 | -$175.21 M(-9.4%) | -$31.30 M(-20.3%) | -$175.21 M(-12.6%) |
| Sep 2022 | - | -$39.28 M(-16.2%) | -$200.42 M(-6.2%) |
| Jun 2022 | - | -$46.89 M(-18.8%) | -$213.61 M(+0.0%) |
| Mar 2022 | - | -$57.74 M(+2.2%) | -$213.58 M(+9.8%) |
| Dec 2021 | -$193.34 M | -$56.51 M(+7.7%) | -$194.45 M(+8.1%) |
| Sep 2021 | - | -$52.47 M(+12.0%) | -$179.83 M(+10.8%) |
| Jun 2021 | - | -$46.86 M(+21.4%) | -$162.26 M(+7.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$38.61 M(-7.8%) | -$150.31 M(+4.1%) |
| Dec 2020 | -$144.34 M(+104.5%) | -$41.89 M(+20.0%) | -$144.34 M(+15.9%) |
| Sep 2020 | - | -$34.91 M(-0.0%) | -$124.57 M(+17.9%) |
| Jun 2020 | - | -$34.91 M(+7.0%) | -$105.66 M(+24.3%) |
| Mar 2020 | - | -$32.64 M(+47.6%) | -$84.98 M(+20.4%) |
| Dec 2019 | -$70.60 M(+61.3%) | -$22.11 M(+38.3%) | -$70.60 M(+15.7%) |
| Sep 2019 | - | -$15.99 M(+12.3%) | -$61.04 M(+15.7%) |
| Jun 2019 | - | -$14.23 M(-22.1%) | -$52.74 M(+4.8%) |
| Mar 2019 | - | -$18.26 M(+45.5%) | -$50.33 M(+15.0%) |
| Dec 2018 | -$43.76 M(+15.6%) | -$12.55 M(+63.1%) | -$43.76 M(+40.2%) |
| Sep 2018 | - | -$7.70 M(-34.9%) | -$31.20 M(+32.7%) |
| Jun 2018 | - | -$11.82 M(+1.2%) | -$23.51 M(+101.2%) |
| Mar 2018 | - | -$11.69 M | -$11.69 M |
| Dec 2017 | -$37.84 M | - | - |
FAQ
- What is Adaptive Biotechnologies annual EBITDA?
- What is the all time high annual EBITDA for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies annual EBITDA year-on-year change?
- What is Adaptive Biotechnologies quarterly EBITDA?
- What is the all time high quarterly EBITDA for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies quarterly EBITDA year-on-year change?
- What is Adaptive Biotechnologies TTM EBITDA?
- What is the all time high TTM EBITDA for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies TTM EBITDA year-on-year change?
What is Adaptive Biotechnologies annual EBITDA?
The current annual EBITDA of ADPT is -$189.27 M
What is the all time high annual EBITDA for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high annual EBITDA is -$37.84 M
What is Adaptive Biotechnologies annual EBITDA year-on-year change?
Over the past year, ADPT annual EBITDA has changed by -$14.06 M (-8.03%)
What is Adaptive Biotechnologies quarterly EBITDA?
The current quarterly EBITDA of ADPT is -$24.57 M
What is the all time high quarterly EBITDA for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high quarterly EBITDA is -$7.70 M
What is Adaptive Biotechnologies quarterly EBITDA year-on-year change?
Over the past year, ADPT quarterly EBITDA has changed by +$36.50 M (+59.77%)
What is Adaptive Biotechnologies TTM EBITDA?
The current TTM EBITDA of ADPT is -$163.50 M
What is the all time high TTM EBITDA for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high TTM EBITDA is -$11.69 M
What is Adaptive Biotechnologies TTM EBITDA year-on-year change?
Over the past year, ADPT TTM EBITDA has changed by +$25.77 M (+13.61%)